Lecanemab, the first medication designed to remove amyloid beta, a protein believed to cause Alzheimer’s, was developed by Japan’s Eisai Co. and its U.S. partner, Biogen Inc. “We believe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback